June Off to a Poor ...
Health Care: Drugs
Amgen Inc (AMGN: NASDAQ)
$67.75 -1.77 | -2.55%
06/01/12 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 15.58B | 15.05B | 14.64B | 15.00B |
| Cost of Sales | 1.66B | 1.50B | 1.34B | 1.52B |
| Gross Operating Profit | 13.92B | 13.56B | 13.31B | 13.49B |
| Selling, General, and Administrative Expenses | 4.49B | 3.98B | 3.82B | 3.79B |
| Research & Development | 3.17B | 2.89B | 2.86B | 3.03B |
| Operating Income before D & A (EBITDA) | 6.27B | 6.68B | 6.62B | 6.67B |
| Depreciation & Amortization | 1.06B | 1.02B | 1.05B | 1.07B |
| Interest Income | 448.00M | 376.00M | 276.00M | 352.00M |
| Other Income - Net | -896.00M | -117.00M | -67.00M | -380.00M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | 4.76B | 5.92B | 5.78B | 5.57B |
| Interest Expense | 610.00M | 604.00M | 578.00M | 316.00M |
| Pre-Tax Income | 4.15B | 5.32B | 5.20B | 5.25B |
| Income Taxes | 467.00M | 690.00M | 599.00M | 1.05B |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | 3.68B | 4.63B | 4.60B | 4.20B |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 3.68B | 4.63B | 4.60B | 4.20B |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 3.68B | 4.63B | 4.60B | 4.20B |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
3.68B | 4.63B | 4.60B | 4.20B |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 3.68B | 4.63B | 4.60B | 4.20B |
| Basic EPS from Continuing Ops. | 4.07 | 4.82 | 4.53 | 3.92 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 4.07 | 4.82 | 4.53 | 3.92 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 4.07 | 4.82 | 4.53 | 3.92 |
| Basic Normalized Net Income/Share | 4.07 | 4.82 | 4.53 | 3.92 |
| EPS fr Continuing Ops. | 4.04 | 4.79 | 4.51 | 3.90 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 4.04 | 4.79 | 4.51 | 3.90 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 4.04 | 4.79 | 4.51 | 3.90 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
4.04 | 4.79 | 4.51 | 3.90 |
| Dividends Paid per Share | 0.56 | 0.00 | 0.00 | 0.00 |
Portfolios with AMGN
- Portfolio NameUser Type
- UserLong Term Stock Picks by Co...
- Contributor5 Low Volatility Low PEG St...
- UserJimboPhi
- UserCorporate Communication cla...
- UserKAREL VON ZOETE
- UserMACHINE RECOMMENDATIONS
- UserMARIA DEL HUERTO
- ContributorHighest-Yielding Drug Stocks
- Contributor10 Health Care Stocks to Watch
- ContributorMost-Searched Stocks for th...
Latest AMGN Headlines from TheStreet
- Symmetry Projections
05.21.12 | 08:05 am - Amgen Inc (AMGN): Today's Featured Drugs Loser 05.18.12 | 05:05 pm
- 5 Cheap, Low-Risk Stocks to Buy 05.18.12 | 07:05 am
- Amgen Stock To Go Ex-dividend Monday (AMGN) 05.11.12 | 08:05 am
- Ex-Dividend Stocks: Target, ConEd 05.11.12 | 07:05 am
- Amgen Inc (AMGN): Today's Featured Drugs Winner 05.10.12 | 05:05 pm
- Amgen Inc (AMGN): Today's Featured Drugs Winner 05.02.12 | 04:05 pm
- Amgen Reaches New 52-Week High (AMGN) 04.25.12 | 01:04 pm
- Amgen Goes to Turkey, Loses Biotech Cred 04.25.12 | 09:04 am
- Amgen's CEO Discusses Q1 2012 Results - Earnings Call Transcript 04.24.12 | 10:04 pm
Press Releases for AMGN
- Amgen Announces Voting Results Of Annual Meeting Of Stockholders - PR Newswire 05.23.12 | 05:05 pm
- Amgen's BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate Of Complete Response In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia - PR Newswire 05.16.12 | 06:05 pm
- Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer - PR Newswire 05.16.12 | 06:05 pm
- Amgen To Present At The Baird Growth Stock Conference - PR Newswire 05.04.12 | 04:05 pm
- Amgen To Present At The Deutsche Bank 37th Annual Healthcare Conference - PR Newswire 05.03.12 | 06:05 pm
- Amgen Receives Complete Response Letter From FDA For XGEVA® SBLA For Prevention Of Bone Metastases - PR Newswire 04.26.12 | 10:04 pm
- Amgen To Acquire Mustafa Nevzat, A Leading Privately Held Turkish Pharmaceutical Company - PR Newswire 04.25.12 | 02:04 am
- A Tribute To George Rathmann, Amgen's Founding CEO (1927-2012) - PR Newswire 04.23.12 | 10:04 pm
- Amgen To Acquire Privately Held KAI Pharmaceuticals - PR Newswire 04.10.12 | 08:04 am
- UCB And Amgen Initiate Sclerostin Antibody Phase 3 Program In Patients With Postmenopausal Osteoporosis - PR Newswire 04.04.12 | 01:04 am
Partner Headlines for AMGN
- Health Care SPDR In Focus Ahead Of Obamacare Decision - Benzinga 05.22.12 | 12:05 pm
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Medgenics Moving In Record Time - Seeking Alpha 05.21.12 | 09:05 am
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
- Top Undervalued High Conviction Outperforming Picks From Eaton Vance's $47 Billion Q1 Filng - Seeking Alpha 04.20.12 | 10:04 pm
- Earnings Preview: Abbott Labs - Analyst Blog - Zacks 04.17.12 | 10:04 am
- The Zacks Analyst Blog Highlights: The Goldman Sachs Group, Lloyd's, Bank of America, JPMorgan Chase and Amgen - Press Releases - Zacks 04.12.12 | 09:04 am
- Market Roundup - Benzinga 04.10.12 | 01:04 pm
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Amgen, Abbott, Teva All Incredibly Undervalued Stocks - Seeking Alpha 04.06.12 | 07:04 am
